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a b s t r a c t
Recombinant subunit vaccines in general are poor immunogens likely due to the small size of peptides and proteins, combined with the lack or reduced presentation of repetitive motifs and missing
complementary signal(s) for optimal triggering of the immune response. Therefore, recombinant subunit vaccines require enhancement by vaccine delivery vehicles in order to attain adequate protective
immunity. Particle-based delivery platforms, including particulate antigens and particulate adjuvants,
are promising delivery vehicles for modifying the way in which immunogens are presented to both the
innate and adaptive immune systems. These particle delivery platforms can also co-deliver non-speciﬁc
immunostimodulators as additional adjuvants. This paper reviews efforts and advances of the Particlebased delivery platforms in development of vaccines against malaria, a disease that claims over 600,000
lives per year, most of them are children under 5 years of age in sub-Sahara Africa.
© 2015 Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).

1. Introduction
Compared to inactivated or live-attenuated whole sporozoites
and whole merozoites, malaria vaccine development strategies
using recombinant subunits and/or synthetic peptides have the
advantage of directing the immune responses toward speciﬁc
targets. These strategies, in general, are amenable to large-scale
controlled manufacturing processes leading to the production
of a well-characterized antigen with acceptable purity at a low
cost. Multiple malaria vaccine targets, most of which are antigens expressed on the surface of parasites in liver, blood, and
mosquito stages, have been evaluated for their ability to induce
protective immunity [1]. Promising protective immunity was often
observed in initial proof-of-concept studies where animals were
immunized with the soluble recombinant proteins formulated with
Freund’s adjuvants. However, the level of protection declined or
was lost in clinical trials when these proteins were formulated
with adjuvants suitable for human use [2,3]. The development of
RTS,S, a recombinant subunit vaccine based on the Plasmodium
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falciparum circumsporozoite protein (PfCSP) present on the surface of infectious sporozoites, has demonstrated the critical roles
of adjuvants and delivery vehicle in order to achieve a signiﬁcant
efﬁcacy. Despite mounting evidence that recombinant PfCSP was
capable of inducing protective immunity against malaria infection,
it was not until certain modiﬁcations to the formulation were made
that the RTS,S vaccine demonstrated a signiﬁcant level of protection against clinical malaria. These modiﬁcations include: (i) PfCSP
was fused to and co-expressed with the hepatitis B Surface antigen
(HBsAg) which then self-assembled to form a virus-like particle
(VLP), with multiple copies of PfCSP presented on the particle surface; and (ii) the VLP was delivered in an oil-in-water emulsion or
a liposomal formulation containing additional immunostimulatory
molecules such as MPL and QS21 [3,4].
VLPs, stable emulsions, and liposomes belong to a category of
nanoparticle-based delivery platforms that have gained increasing interests in recent years due to their ability to enhance the
immunogenicity of recombinant subunit vaccines (Table 1). A
nano-sized particle displaying high-density repetitive antigens or
epitopes, devoid of invasive pathogenic materials yet permitting
inclusion of desired immunostimulatory molecules, is an ideal
representation that enables incorporation of quality-by-design
concepts during vaccine development. There are multiple beneﬁts
to these platforms. First, a successful immune response, be it
a pathogen or a vaccine, requires the ability of antigens to be
taken up by antigen presenting cells (APCs), processed and presented to immune effectors. At a size comparable to pathogenic
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Table 1
Particle-based delivery platforms.

Particulate antigens

Type

Characteristics*

Reference

Virus-like particles (VLP)

Viral capsid protein self-assembled to form a stable core;
exogenous target antigens are displayed repetitively on the surface
by recombinant fusion or chemical conjugation to the viral capsid
protein. A lipid membrane may be present for certain VLPs (e.g.
retrovirus derived VLPs)
Lipid-enveloped VLPs without viral capsid core; exogenous target
antigens are displayed repetitively on the envelop surface.
Antigens can be inserted by chemical conjugation to the lipids or
through the natural transmembrane domain present on native
proteins; co-delivery of additional immunostimulants possible
Polypeptide core scaffold formed by multiple coiled-coils
oligomerization domains; target antigens are present at the N- and
C-termini of the scaffold polypeptide, and displayed repetitively
on the core surface
Polypeptides, polysaccharides, or recombinant proteins are
chemically conjugated to a protein carrier, and cross-linked to
form a matrix
Micron-sized; peptidoglycan (PGN) matrices derived from food
grade bacteria; target antigens are recombinantly tagged with a
PGN-binding domain and displayed on the matrix surface by
non-covalent interaction with PGN
Lipid bilayer vesicles with an aqueous core; target antigen may be
displayed on vesicle surface, intercalated in lipid bilayer, or
entrapped in aqueous core; co-delivery of additional
immunostimulants
Nano-to-micron-sized, oil droplets are emulsiﬁed in bulk water
phase; target antigens may interact with the oil droplets by
hydrophobicity or electrostatic force; co-delivery of additional
immunostimulants
Nano-to-micron-sized, water droplets are emulsiﬁed in bulk oil
phase; target antigens are entrapped in the water droplets
A cage-like structure formed at interactions between
phospholipids and saponin-cholesterol micelles; target antigens
are entrapped in the void space of the cage
Nano-to-micron-sized; bio-degradable synthetic polymers such as
poly (lactic-co-glycolic) acid (PLGA); target antigens are entrapped
within the polymer
Micron-sized; porous aggregates of ﬁbrous aluminum hydroxide
or plate-like aluminum phosphate; target antigens are adsorbed to
aluminum salts by electrostatic attractive force or trapped in void
spaces within the aggregates

[5,64]

Virosomes

Self-assembling polypeptide
nanoparticles (SAPN)

Antigen-carrier conjugates

BLPs

Particulate Adjuvants

Liposomes

O/W emulsions

W/O emulsions
Iscomatrix

Biodegradable polymers

Aluminum salts

*

[13]

[18]

[34]

[8,9]

[40,42]

[51,65]

[66]
[67]

[61]

[68]

The particles are nano-sized unless otherwise indicated.

microorganisms, the antigen-bearing nanoparticles are more easily
recognized and efﬁciently taken up by APCs at the site of vaccine
injection [5]. Second, Pattern Recognition Receptors (PRRs) of the
innate immune system are the ﬁrst line of host defense against a
pathogen. PRRs recognize speciﬁc Pathogen-Associated Molecular
Patterns (PAMPs) that leads to the induction of a proinﬂammatory
response responsible for the induction of both innate and subsequently adaptive immunity. Presence of high-density repetitive
epitopes on particle surface facilitates B-cell activation through
cell surface receptor oligomerization and the generation of speciﬁc
antibodies with higher afﬁnity [6,7]. Third, prolonged and controlled release of target antigens from the particle will result in a
“depot” effect favoring the induction of lasting immune responses.
Last but not least, the particle may allow co-delivery of antigen
and immunostimulatory adjuvants such as toll-like receptor (TLR)
agonists to the same APC, ensuring a speciﬁc APC activation.
This review aims to summarize efforts and advances in applying nanoparticle-based delivery platforms to enhance the immune
response of malaria vaccines based on recombinant antigens or
synthetic peptides. The focus is directed toward the works published from 2010 and onwards. Though they will not be discussed in
this review, it is worth noting that aluminum salts and BacteriumLike Particle (BLP) are also particulate in nature. However, they are
micron-sized, and their modes of action in immune enhancement
differ from those of nanoparticles. To date, aluminum salts do not
appear to provide adequate adjuvanticity to recombinant malaria

vaccine candidates. On the other hand, BLPs have shown some
promising immune enhancement that warrant further exploration
[8,9]. RTS,S, a particulate antigen formulated in particulate adjuvant, is the subject of a separate review article in this issue [200].

2. Particulate antigens
2.1. Virus-like particles
There are two main types of VLPs: (i) the non-enveloped VLPs
made of viral capsid proteins that self-assemble into stable structures. The vaccine target antigens can be recombinantly fused to
the viral protein and displayed on the particle surface; and (ii)
enveloped VLPs harboring a lipid membrane with the vaccine target
antigens anchored at the surface. Among enveloped VLPs there are
two categories: those having a core of proteins forming a capsidlike structure surrounded by a lipid membrane, and those devoid
of a protein core and having only a lipid membrane with the target
antigens embedded, such as the inﬂuenza virosomes. In the latter
case, target antigens could be recombinant proteins or synthetic
peptides that are conjugated to lipid tails for membrane anchoring,
or it could be native proteins with their own transmembrane and
cytoplasmic domain.
Utilizing recombinant expression in Tobacco plants as a platform technology, Jones et al. constructed an expression vector
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encoding Pfs25, a P. falciparum ookinete surface protein and a
transmission blocking vaccine candidate, fused to the coat protein
(CP) of Alfalfa mosaic virus [10]. The puriﬁed recombinant product composed of the Pfs25-CP fusion protein and two truncated
CP polypeptides, in planta co-assembled to form VLPs 20 nm in
diameter. The requirement of the truncated viral coat protein in the
assembly process is reminiscent of RTS,S, where assembly of PfCSPHBsAg VLP also required truncated HBsAg [3]. Interestingly, mice
immunized with Pfs25-CP VLPs formulated in Alhydrogel® elicited
high-titer, long-lasting transmission blocking antibodies even with
a single vaccination dose. A Phase 1 trial with Pfs25-CP VLP formulated with Alhydrogel® has been conducted in healthy adults in the
USA though the results are not yet published [101].
Enhancement of antibody responses by VLP was also demonstrated in study in rhesus monkeys immunized with soluble and
particulate versions of a vaccine based on Plasmodium vivax CSP,
a.k.a CSV [11]. Four groups of rhesus monkeys were immunized
with two doses each of a soluble form of the vaccine (VMP001)
or the particulate version (CSV-S,S). The latter are VLPs that are
formed by fusing VMP001 to hepatitis B Surface antigen (CVS-S)
and co-expressing with free HBsAg to form CSV-S,S. While both
vaccines, formulated with AS01 which consists of MPL, QS21 and
liposomes, induced robust cellular and humoral responses, CSVS,S generated higher antibody titers, particularly with regard to a
potentially protective B cell epitope.
Another way to present target antigens on the surface of a VLP is
by chemical conjugation of a recombinant antigen to the surface of a
preassembled VLP. A well tested example of this principle is the VLP
formed from the capsid protein of the bacteriophage Q␤· The amino
group of the surface exposed Lysine residues are reacted with a
bi-functional chemical cross-linker which is subsequently reacted
with the target antigen engineered to contain a reactive Cysteine
residue. The resulting VLP products present repetitive arrays of
the target epitope on the particle surface. This platform has been
evaluated extensively in therapeutic vaccines such as ones against
nicotine dependence, hypertension, and Alzheimers diseases [12].
The Qb VLP has also been used as a core to present multiple copies
of recombinant Pfs25 on its surface. Immunizing mice with the
Pfs25-Q␤ VLP, formulated with or without Alhydrogel® , induced
anti-Pfs25 antibody titers higher than that of Pfs25-EPA conjugates. The antibodies displayed transmission blocking activity, and
stronger IgG2 and IgG3 titers indicating a Th1 response induced by
Pfs25-Qb VLP [201].
Virosomes, enveloped VLPs constituted of phospholipids and
viral proteins, may incorporate the target antigens by coupling
them to lipid components of the envelope. Although virosomes
can be produced from a variety of enveloped viruses, the inﬂuenza
virus has been the dominant substrate for producing virosomebased vaccines [13]. The virosomal delivery platform beneﬁted
from an extensive human safety proﬁle, as demonstrated over
the last 20 years in adults as well as children, elderlies, and
immune-compromised populations [14,15]. Early efforts of conjugating virosomes with peptides derived from repeat region of
PfCSP and an ectodomain of the P. falciparum apical membrane
antigen-1 (PfAMA1), a micronemal protein involved in merozoite
invasion led to several clinical trials. When evaluated individually, both PfCSP-virosome (PEV302T) and PfAMA1-virosome
(PEV301T) formulations demonstrated excellent safety, tolerability and immunogenicity, though none of the participants were
protected against blood stage infection in a challenge study [13].
However, when PEV302T and PEV301T were administered in combination, a reduction in the malaria incidence rate was observed
in children aged 5–9 years old, indicating the value of a multivalent vaccine approach [16]. The virosome was also used to deliver
GMZ2, a recombinant fusion protein consisting of the N-terminal
portion of the P. falciparum Glutamate Rich Protein (PfGLURP)

and C-terminal fragment of the P. falciparum Merozoite Surface
Protein 3 (PfMSP3). Although the antibody titer elicited by the
unadjuvanted GMZ2-virosome conjugate was merely comparable
to the titer by GMZ2 formulated with alum [17], the result seemed
encouraging for 2 reasons: (i) In addition to small peptide focusing
on key epitopes (also called mimotopes), the virosome is a versatile platform allowing also the delivery of small-to-large size (∼2 to
100 kDa) recombinant antigens, some in dimeric or trimeric forms;
and (ii) Virosome platform still has the potential to further enhance
immunity if additional and relevant adjuvants are inserted into
the lipid membrane or packaged within the aqueous core of the
virosomes.
2.2. Self-assembling polypeptide nanoparticles (SAPNs)
Self-Assembling Polypeptide Nanoparticles (SAPN) are based
on the alpha-helical coiled-coil oligomerization motifs present in
protein sequences that allow them to self-assemble into welldeﬁned ordered structures. The basic building block of the SAPN
is a monomeric polypeptide chain containing one pentameric
and one trimeric coiled-coil oligomerization domains. Driven by
these domains, about 60 polypeptide chains self-assemble into an
ordered structure with icosahedral symmetry, exposing both Nand C terminal ends on the surface [18]. Extending the polypeptide
chain with target epitopes would allow presentation of the target
epitopes in a repetitive array on the particle surface.
To test this novel concept for development of malaria vaccines,
Kaba et al. designed and recombinantly produced a polypeptide
chain based on the pentameric coiled-coil sequence of cartilage
oligomeric matrix protein (COMP), a de novo-designed trimeric
coiled-coil, and a B cell immunodominant repeat epitope of Plasmodium berghei CSP that assembled into ∼25 nm particles [19].
Immunized mice generated CD4+ T cell-dependent, high-titer,
high-avidity long-lasting antibody responses that were capable of
protecting mice challenged with P. berghei sporozoites. In order to
develop the SAPN platform for human use, the pentameric coiledcoil forming sequence was switched from the COMP domain to a de
novo designed Tryptophan-zipper to prevent possible cross reactivity [20,21]. Interestingly the replacement of the COMP sequence
resulted in a loss of immunogenicity and protective efﬁcacy in mice,
which was restored by introducing a universal helper T cell epitope
PADRE into the trimeric coiled-coil domain. These second generation constructs were designed to expose the immunodominant B
cell epitope from the repeat region of P. falciparum CS at the surface
of the SAPNs and also included three P. falciparum CD8+ epitopes
within the scaffold of the nanoparticle. The long-lasting antibodies
elicited by the new SAPNs were capable of protecting mice challenged with Tg-Pb/PfCSP, a transgenic P. berghei parasite expressing
PfCSP on its sporozoite surface [20]. Using SAPNs that contained
heterologous B cell epitopes and/or lacked the CD8 epitopes, protection was demonstrated to be mediated via both antibodies and
CD8 T cells. The process to produce these SAPNs is amenable to
cGMP manufacturing [22] and they are currently being developed
further for human testing.
2.3. Antigen-carrier conjugates
Development of chemical conjugate vaccines, in general, is
based on early work using non-immunogenic targets or haptens
chemically conjugated to a “carrier protein”. Active immunization with hapten-carriers enabled production of hapten speciﬁc
antibodies due to appropriate communication between T cells
and B cells [23]. These observations supported production of
chemically conjugated polysaccharide vaccines that switch T
cell-independent antigen presentation of polysaccharide moieties
to T cell-dependent antigens for use in licensed vaccines for
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predominately young children against Neisseria meningitides,
Haemophilus inﬂuenza type b and Streptococcus pneumoniae [24].
Various carriers are used in these commercial vaccines including
cross reactive material of diphtheria detoxiﬁed toxin bearing an
amino acid substitution, identiﬁed as CRM197 ; Tetanus toxoid (TT),
and meningococcal outer membrane protein complex (OMPC) [25].
Encouraging results were obtained by conjugating Pfs25 to
OMPC: the conjugation signiﬁcantly enhanced the antibody titers in
mice, rabbits, and non-human primates. Chemical coupling did not
seem to affect functional epitopes, as the correlation between the
conjugate-induced antibody titres and their transmission reducing
activities was similar to that induced by soluble Pfs25 formulated with Montanide® ISA51, a water-in-oil formulation. More
interestingly, the antibody response induced by the conjugate was
sustained for 2 years, and recalled by a booster dose of Pfs25 formulated with an aluminum adjuvant [26]. It was noted that OMPC
differs from other carriers in that its proteins are present in a liposomal form containing lipids, including lipopolysaccharide, a natural
adjuvant. The potential for development of a Pfs25-OMPC chemical
conjugate vaccine is under further investigation.
A well-deﬁned protein carrier, the recombinant Pseudomonas
aeruginosa detoxiﬁed toxin, ExoProtein A (rEPA) produced in
Escherichia coli, has also demonstrated the capacity of immune
enhancement [27]. Although rEPA is not yet a component of any
licensed vaccine, it appears to be safe in humans including infants
[28–31]. Early preclinical studies evaluating the immunogenicity
of chemically conjugated recombinant Pfs25 and Pfs28 to rEPA
formulated on Alhydrogel® demonstrated an enhanced functional
antibody response, which was further enhanced by adding CpG
[27,32,33]. A pilot-scale production process was developed to manufacture a Pfs25-EPA conjugate in compliance with current good
manufacturing practices [34], and a Pfs25-EPA/Alhydrogel® formulation was tested in Phase 1 trials in US and Mali adults [102,202].
Of particular interest, the Pfs25-EPA chemical conjugate appears
as a nanoparticle in solution with a similar diameter to VLPs of
the RTS,S vaccine [34]. A second Phase 1 trial in US and Mali
adults is in progress testing a second generation of Pfs25-EPA conjugate vaccine, using a recombinant Pfs25 protein without any
heterologous amino acids, alone and in combination with a recombinant subdomain of a P. falciparum gamete surface protein Pfs230
chemically conjugated to EPA [103,203]. Unfortunately, chemical
conjugation of larger recombinant proteins may not provide a similar immunological beneﬁt. For example, chemical conjugation of
two recombinant proteins larger than 40 kDa to rEPA failed to provide any signiﬁcant enhancement in immunogenicity when tested
in small animals [35] [204].
Chemical conjugation of the nontoxic cholera toxin B subunit
with recombinant Pvs25, a Pfs25 ortholog on P. vivax zygote surface,
has been reported to increase the transmission reducing efﬁcacy
against P. vivax [36]. Miyata et al. also developed a novel strategy
to increase immune responses by creating genetic fusion proteins
to target speciﬁc APCs. The fusion complex was composed of three
physically linked molecular entities: (i) A vaccine antigen, (ii) A
multimeric alpha-helical coiled-coil core, and (iii) An APC-targeting
ligand linked to the core via a ﬂexible linker. Immunization of mice
with the tricomponent complex fused to Pvs25 induced a robust
antibody response and conferred substantial levels of P. vivax transmission blockade [37].
Epitope repetition within conjugates, in addition to particle
formation is likely to be another mechanism of immune enhancement. Kubler-Kielb et al. demonstrated that polymerizing Pfs25
by chemical conjugation to itself improved Pfs25 immunogenicity and response longevity in mice [38]. The multimeric Pfs25 core,
in addition to its own merit as a target antigen, was also used as a
carrier for conjugation with the central repeats of PfCSP. The conjugation enhanced immunogenicity of the PfCSP repeats in mice [39],
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likely due to the epitope repetition and the particulate nature of
the conjugates.
3. Particulate adjuvants
3.1. Liposomes
Liposomes are self-assembling spherical vesicles composed of
a phospholipid bilayer enclosing an aqueous core. Liposomes can
also be made as multilamellar in which multiple concentric lipid
bilayers are separated by aqueous layers. Liposomes have versatile
ways to deliver target antigens and additional immunomodulators
as adjuvants. Depending upon chemical and biochemical properties, water-soluble target antigens can be entrapped within the
aqueous phase, and lipophilic molecules can be intercalated within
the lipid bilayer. Antigens and adjuvants can also be attached to
the surface of liposomes by adsorption, covalent conjugation, and
electrostatic interactions. Liposomes have been broadly applied to
enhance T and B cell responses to subunit vaccines candidates,
including several being evaluated in humans [4,40–42].
The most advanced application of the liposomal delivery system in malaria vaccine development is AS01, an Adjuvant System
comprised of liposome, QS21, and MPL, a TLR4 agonist. In completion of a multi-center Phase 3 trial of RTS,S/AS01 involving >15,000
children including 6000 infants in malaria endemic regions, the
adjuvant has an extensive safety proﬁle [200]. In addition to RTS,S,
several recombinant malaria antigens formulated with AS01 have
been evaluated in humans. These include LSA-NRC, a recombinant protein comprised of N-and C-terminal regions and two of
the central repeats of P. falciparum Liver Stage Antigen 1 and a
candidate vaccine to block merozoite egress from hepatocytes, in
a Phase 1 trial in US adults followed by a Phase 2a sporozoite
challenge [43]; AMA1, a recombinant ectodomain of P. falciparum
merozoite apical membrane antigen 1, in a Phase 1 trial in US
adults followed by a Phase 2a sporozoite challenge [44]; and
MSP142 , the 42 kDa N-terminal region of P. falciparum merozoite
surface protein 1, in a Phase 1 trial in US adults followed by a
second Phase 1 trial in Kanyan adults [45]. All formulations demonstrated reassuring safety proﬁles. Despite the fact that none of
these formulations showed any protection in challenge studies
(for PfLSA-NRC and PfAMA1) or in growth inhibition assay (for
PfMSP142 ), all have elicited high titers of speciﬁc antibodies. In
addition, PfLSA-NRC/AS01 formulation induced higher CD4+ T cell
response than did PfLSA-NRC formulated with AS02, another Adjuvant System and an oil-in-water emulsion also containing MPL and
QS21 (see Section 3.2), indicating the role of liposomal formulation
in induction of cellular responses [43]. However, no signiﬁcant difference was found in CD4 responses induced by PfAMA1/AS01 or
by PfAMA1/AS02 [44].
The PfAMA/AS01 and PfAMA1/AS02 were also evaluated in UK
healthy adults, followed by a challenge with blood-stage parasites
[104]. Also being evaluated in human trials were PfCelTOS/AS01
[105] and PvCSP/AS01 [106], two vaccine candidates to block
sporozoite invasion of hepatocytes by P. falciparum and P. vivax
parasites, respectively. In both studies the participants receiving
the full intended dose were challenged with falciparum or vivax
sporozoites. Anticipated analysis will shed light whether protective efﬁcacies, if any, are associated with B cell or T cell responses,
and the role of the adjuvant in these responses.
GLA-LSQ is a novel liposomal adjuvant consisting of liposome,
QS21 and Glucopyranosyl Lipid A (GLA). Since GLA is a known TLR4
agonist [46], GLA-LSQ is expected to have similar adjuvanticity
as AS01. With a recombinant full-length Pf CSP produced in Pseudomonas ﬂuorescens expression platform, NOE et al. evaluated the
solubilized rPfCSP in various delivery systems including GLA-LSQ,
GLA in stable emulsion (GLA-SE), and aluminum salts, with the
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intention to select one for human use. Whereas the GLA-LSQ and
GLA-SE formulations were comparable in antibody induction, in
functional assays including in vitro inhibition of sporozoite invasion
and in vivo protection against Tg-Pb/PfCSP sporozoite challenge,
rPfCSP/GLA-LSQ formulation was a clear winner in induction of
cellular and lasting antibody responses. Partial protection against
sporozoite challenge was observed, and it would be interesting
to know whether the protected animals had higher humoral and
cellular responses [47].
While it is unclear how liposomes in AS01 and GLA-LSQ interact
with the target antigens, the cationic liposomal adjuvants clearly
attract target antigens with opposite charges through electrostatic
interaction. One of these is CAF01, a novel liposomal adjuvant
composed of cationic lipid vesicles stabilized with a glycolipid
immunostimulant TDB, a synthetic analogue of mycobacterial cell
wall. A CAF01 formulated vaccine candidate against tuberculosis
was shown to be safe and tolerable in humans, and induced strong
lasting T-cell responses. However, there was no detectable antibody
responses in humans, in contrast to observation in preclinical animal studies [42]. CAF01 has also been used to formulate PyMSP119
[48], a recombinant protein based on the 19 kDa C-terminal region
of Plasmodium yoelii MSP1, and DBL4-ID4, a recombinant subunit
of P. falciparum VAR2CSA and a vaccine candidate to protect women
against placental malaria [49]. PyMSP119 /CAF01 induced signiﬁcantly higher IgG1 and IgG2 antibodies in mice than did the alum
formulation, and conferred a stronger partial protection in mice
from a blood stage parasite challenge. In the DBL4-ID4/CAF01
study, the DBL4-ID4 was also formulated with 2 other adjuvants: Alhydrogel and Montanide ISA720, a water-in-oil emulsion.
Although antibody titers induced by all 3 formulations were similar,
the DBL4-ID4/CAF01 induced IgGs displayed a stronger inhibition
of infected erythrocytes binding to chondroitin sulphate proteoglycans, and a stronger binding to the target antigen DBL4-ID4.
Interbilayer-crosslinked multilamellar vesicle (ICMV) is another
type of liposomal delivery system that shows promise. Moon
et al. reported enhanced antigen-speciﬁc humoral responses when
ICMVs were used to co-deliver a TLR4 agonist along with PvCSP
that was either entrapped within the vesicle or entrapped as well
as displayed on the surface of the vesicles ICMV [50]. The resulting ∼180 nm particles elicited antibodies that were 9-fold higher
in the formulation with entrapped and surface-displayed PvCSP
compared to the group which did not have antigen on the surface. This vaccine delivery method allowed dose-sparing, generated
a more balanced Th1/Th2 response with high avidity long-lasting
antibodies. The response correlated with the induction of Tfh cells in
germinal centers that formed adjacent to the vaccination site. These
observations seem consistent with the mechanisms of immune
enhancement by a particulate delivery system.
3.2. Stable emulsion
Emulsion-based nanoparticle adjuvants include oil-in-water
(O/W) emulsions that interact with target antigens mainly by
hydrophobic or electrostatic forces, and water-in-oil (W/O) emulsions that entrap target antigens in water droplets. They have been
widely used in vaccine development, and the O/W emulsion MF59
and AS03, and W/O emulsion Montanide® ISA51 are components
of several licensed vaccines [51].
Following unsatisfactory outcomes in animal studies with MF59
adjuvanted malaria antigens including P. falciparum AMA1, MPS1,
SERA, Pfs25, and P. vivax Duffy-binding protein, no further clinical
development was justiﬁed with the adjuvant [52]. Despite superb
immune-enhancement offered by Montanide® ISA51 and a similar W/O emulsion Montanide® ISA720, the adjuvants ceased to
be the choice for clinical development due to high rate of local
reactogenicity and unexpected systemic reactions in Phase 1 trials

[53,54]. On the other hand, AS02, an O/W emulsion with additional
immunostimulants MPL and QS21, has been shown in clinical trials
to enhance immune responses of multiple malaria antigens including P. falciparum AMA1, MSP1 and LSA1, though the adjuvant did
not increase their protective efﬁcacy [43,44]. Although AS02 was
the initial adjuvant that delivered RTS,S with proven clinical efﬁcacy, it was outperformed by RTS,S/AS01 formulation for induction
of humoral and cellular immunity, and protective efﬁcacy [4,55].
GLA-SE, an O/W emulsion containing TLR4 agonist, was
expected to have similar adjuvanticity as AS01 due to their similar composition except for lacking QS21 in GLA-SE. Indeed, GLA-SE
has a demonstrated capacity to elicit strong Th1 type immune
responses. PbCSP and PfCelTOS formulated with GLA-SE induced
higher level of IgG2 antibodies and more INFγ-producing cells in
mice [56,57]. GLA-SE also has a broad safety proﬁle in humans:
It has been injected in hundreds of humans in multiple Phase 1
trials evaluating vaccine candidates against various diseases. The
completed or currently on-going Phase 1 trials with GLA-SE formulated recombinant malaria antigens include PfCelTOS, PfAMA1, and
PfP27A, a synthetic polypeptide corresponding to the unstructured
domain of P. falciparum Trophozoite exported protein 1 (Tex1)
[107]. While results of these trials are not yet published, the attempt
has been made to further increase the immune enhancing capacity
of GLA-SE by inclusion of additional TLR7/8 agonists, such as R848.
Unfortunately PvSCP formulated with GLA/R848-SE induced lower
humoral and cellular responses in mice [58].
3.3. Others
Several other particulate delivery systems, including ISCOMs
and biodegradable polymers, caught interest of malaria vaccine
developers.
ISCOMs are cage-like particles composed of phospholipids,
saponin-cholesterol micelles and the antigens incorporated into
particles through hydrophobic interaction, which requires a
hydrophobic tag if the target antigen is hydrophilic [59]. Subsequently, by using different lipids, Isomatrix® became a versatile
adjuvant system that can entrap any type of target antigens, deliver
the target antigens to APCs, and enhance both B cell and T cell
responses in multiple species. Isomatrix® has been applied to over
one thousand volunteers in Phase 1 and Phase 2 trials evaluating prophylactic and therapeutic vaccines, and was shown to be
well tolerated. Regarding malaria antigens, Przysiecki et al. evaluated immunogenicity of (NANP)6 -OMPC/MAA, an alum adsorbed,
OMPC-conjugated peptide corresponding to the central repeats of
PfCSP, with and without Isomatrix® . In in-bred mice, addition of
Isomatrix® to the alum formulation did not have much effect on
antibody titer, while in rhesus monkeys, addition of Isomatrix® in
formulation induced a long-lived high-level anti-repeat antibodies
compared to the animals immunized with the formulation without Isomatrix® [60]. The observations prompted cautions of using
alum-formulation as a bench marker for adjuvant selection in mice,
as the species and the adjuvant is widely used in initial proof-ofconcept studies.
Biocompatible and biodegradable polymeric nanoparticles may
represent a promising new technology for improved immune
responses [61]. Their ability to sustain and control the release of
the entrapped antigens and their delivery to APCs raised hope for
eliciting long-lasting immune responses. Among a wide variety of
synthetic polymers used to prepare nanoparticles, poly (lactic-coglycolic) acid (PLGA) has been evaluated extensively and is already
in several FDA-approved therapeutic delivery devices. By emulsifying PLGA and maleimide-activated lipids, Moon et al. created
new PLGA particles enveloped with a lipid bilayer, which allowed
covalent conjugation of thiolated PvCSP on the particle surface [62].
The resulting PvCSP-NP elicited durable antibody with signiﬁcantly
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higher titers and more balanced Th1/Th2 responses, compared to
the PvCSP monomer. Antibody titers raised by PvCSP-NP were able
to agglutinate P. vivax sporozoites, and exhibited higher avidity
and afﬁnity toward the recombinant protein. Using a derivative
of PLGA, Dinglasan et al. prepared a nano-to-micron-sized particle incorporated with recombinant AnAPN1, an Anopheles gambiae
aminopeptidase in mosquito midgut and a TBV candidate [63].
Immunization of the An-APN1 loaded particle induced functional
antibodies, as measured by direct feeding of mosquitoes on immunized mice challenged with P. berghei, even 6 months after a single
dose of vaccination.
4. Reﬂection and conclusion
Since a strong safety proﬁle in humans is paramount for development of prophylactic vaccines, a rather conservative approach
has been taken in adjuvant/delivery selection for recombinant
subunit-based malaria vaccine candidates. Nearly all clinical trials
with recombinant malaria antigens started with aluminum salts as
the adjuvant. Now it has become a consensus that recombinant
subunit vaccines are unlikely to achieve desired protective efﬁcacy without an appropriate delivery vehicle that includes not only
adjuvant but also a proper antigen presentation format. Particulate delivery of vaccine antigens is advantageous as it can simulate
a pathogen-mimicry by presenting the proteins as larger moieties, allowing more efﬁcient uptake by APCs, stimulating innate
immune responses through Pattern Recognition Receptors (PRRs),
and providing depot effect for lasting responses. The licensure
of particle-based vaccines such as HPVs and the accumulation of
safety data in other vaccines in clinical trials has raised the hope
of applying such delivery systems in malaria vaccine development
without compromising the safety precaution.
Selection of a suitable delivery platform for a particular malaria
antigen has been and will likely remain to be empirical. There are
still technical hurdles in optimizing the delivery platforms, particularly with regard to particulate antigens such as VLPs, SAPNs,
and antigen-carrier conjugates. There seems to be a size and density limit to the target antigens to be displayed on the particle
surface. To remedy this we need a clear understanding as well as
tools for characterization of the functional epitopes or subdomains
within the target antigen, and their native conformation. The processes and conditions to preserve the native conformation during
the synthetic or recombinant production of the target epitope or
antigen have to be empirically determined. Other needs that have
to be empirically determined are the processes and conditions to
increase the antigen to core/carrier loading ratios. Finally during
selection of the delivery platforms, the immune status of the target population needs to be considered. New born babies and young
infants may have different adjuvant requirement as older children
and adults. Vaccine must be “tailored” according to the immune
status of subjects to be vaccinated.
While animal models are always used in initial proof-of-concept
studies, the deﬁnitive evaluation of a delivery platform has to be
trials conducted humans. It is an exciting time as multiple clinical trials have been conducted or are on-going to evaluate several
particle-based delivery of subunit malaria antigens. Outcomes of
these trials will not only help the selection of safe and potent delivery vehicles, but will also shed light on whether and/or how animal
models predict the immune response and the protective efﬁcacy in
humans.
Disclaimer
The opinions or assertions contained herein are the private
views of the authors and are not to be construed as ofﬁcial or as
reﬂecting the views of either the Department of Health and Human

7523

Services, the Department of the Army, the Department of Defense
or the U.S. Government. YW and DLN are supported by Division of
Intramural Research, NIAID, NIH.
References
[1] Birkett AJ, et al. Malaria vaccine R&D in the decade of vaccines: breakthroughs,
challenges and opportunities. Vaccine 2013;31(Suppl. 2):B233–43.
[2] Ellis RD, et al. Blood stage vaccines for Plasmodium falciparum: current status
and the way forward. Hum Vaccin 2010;6(8):627–34.
[3] Heppner Jr DG, et al. Towards an RTS, S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of
Research. Vaccine 2005;23(17–18):2243–50.
[4] Regules JA, Cummings JF, Ockenhouse CF. The RTS, S vaccine candidate for
malaria. Expert Rev Vaccines 2011;10(5):589–99.
[5] Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010;10(11):787–96.
[6] Liu W, Chen YH. High epitope density in a single protein molecule signiﬁcantly
enhances antigenicity as well as immunogenicity: a novel strategy for modern
vaccine development and a preliminary investigation about B cell discrimination of monomeric proteins. Eur J Immunol 2005;35(2):505–14.
[7] Jegerlehner A, et al. Regulation of IgG antibody responses by epitope density
and CD21-mediated costimulation. Eur J Immunol 2002;32(11):3305–14.
[8] Ramasamy R, et al. Immunogenicity of a malaria parasite antigen displayed by
Lactococcus lactis in oral immunisations. Vaccine 2006;24(18):3900–8.
[9] Nganou-Makamdop K, et al. Bacterium-like particles as multi-epitope delivery
platform for Plasmodium berghei circumsporozoite protein induce complete
protection against malaria in mice. Malar J 2012;11:50.
[10] Jones RM, et al. A plant-produced Pfs25 VLP malaria vaccine candidate induces
persistent transmission blocking antibodies against Plasmodium falciparum in
immunized mice. PLoS ONE 2013;8(11):e79538.
[11] Vanloubbeeck Y, et al. Comparison of the immune responses induced by soluble and particulate Plasmodium vivax circumsporozoite vaccine candidates
formulated in AS01 in rhesus macaques. Vaccine 2013;31(52):6216–24.
[12] Bachmann MF, Jennings GT. Therapeutic vaccines for chronic diseases:
successes and technical challenges. Philos Trans R Soc Lond, B: Biol Sci
2011;366(1579):2815–22.
[13] Moser C, et al. Inﬂuenza virosomes as vaccine adjuvant and carrier system.
Expert Rev Vaccines 2013;12(7):779–91.
[14] Ambrosch F, et al. Rapid antibody response after vaccination with a virosomal
hepatitis a vaccine. Infection 2004;32(3):149–52.
[15] Ansaldi F, et al. Head-to-head comparison of an intradermal and a virosome
inﬂuenza vaccine in patients over the age of 60: evaluation of immunogenicity, cross-protection, safety and tolerability. Hum Vaccin Immunother
2013;9(3):591–8.
[16] Cech PG, et al. Virosome-formulated Plasmodium falciparum AMA-1 & CSP
derived peptides as malaria vaccine: randomized phase 1b trial in semiimmune adults & children. PLoS ONE 2011;6(7):e22273.
[17] Tamborrini M, et al. Immunogenicity of a virosomally-formulated Plasmodium
falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in
comparison to adjuvanted formulations. Malar J 2011;10:359.
[18] Raman S, et al. Structure-based design of peptides that self-assemble into regular polyhedral nanoparticles. Nanomedicine 2006;2(2):95–102.
[19] Kaba SA, et al. A nonadjuvanted polypeptide nanoparticle vaccine confers
long-lasting protection against rodent malaria. J Immunol 2009;183(11):
7268–77.
[20] Kaba SA, et al. Protective antibody and CD8+ T-cell responses to the Plasmodium
falciparum circumsporozoite protein induced by a nanoparticle vaccine. PLoS
ONE 2012;7(10):e48304.
[21] Wahome N, et al. Conformation-speciﬁc display of 4E10 and 2F5 epitopes on
self-assembling protein nanoparticles as a potential HIV vaccine. Chem Biol
Drug Des 2012;80(3):349–57.
[22] Guo Q, et al. Expression, puriﬁcation and refolding of a self-assembling protein
nanoparticle (SAPN) malaria vaccine. Methods 2013;60(3):242–7.
[23] Parker DC. The carrier effect and T cell/B cell cooperation in the antibody
response. J Immunol 2013;191(5):2025–7.
[24] Kelly DF, Moxon ER, Pollard AJ. Haemophilus inﬂuenzae type b conjugate vaccines. Immunology 2004;113(2):163–74.
[25] Pichichero ME. Protein carriers of conjugate vaccines: characteristics, development and clinical trials. Hum Vaccin Immunother 2013;9(12.).
[26] Wu Y, Craig A. Comparative proteomic analysis of metabolically labelled proteins from Plasmodium falciparum isolates with different adhesion properties.
Malar J 2006;5:67.
[27] Qian F, et al. Conjugating recombinant proteins to Pseudomonas aeruginosa
ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine
candidates. Vaccine 2007;25(20):3923–33.
[28] Passwell JH, et al. Age-related efﬁcacy of Shigella O-speciﬁc polysaccharide
conjugates in 1-4-year-old Israeli children. Vaccine 2010;28(10):2231–5.
[29] Passwell JH, et al. Safety and immunogenicity of Shigella sonnei-CRM9 and
Shigella ﬂexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old
children. Pediatr Infect Dis J 2003;22(8):701–6.
[30] Thiem VD, et al. The Vi conjugate typhoid vaccine is safe, elicits protective levels
of IgG anti-Vi, and is compatible with routine infant vaccines. Clin Vaccine
Immunol 2011;18(5):730–5.

7524

Y. Wu et al. / Vaccine 33 (2015) 7518–7524

[31] Lin FY, et al. The efﬁcacy of a Salmonella typhi Vi conjugate vaccine in two-toﬁve-year-old children. N Engl J Med 2001;344(17):1263–9.
[32] Qian F, et al. Enhanced antibody responses to Plasmodium falciparum Pfs28
induced in mice by conjugation to ExoProtein A of Pseudomonas aeruginosa
with an improved procedure. Microbes Infect 2009;11(3):408–12.
[33] Qian F, et al. Addition of CpG ODN to recombinant Pseudomonas aeruginosa
ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of
responders. Vaccine 2008;26(20):2521–7.
[34] Shimp Jr RL, et al. Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle. Vaccine
2013;31(28):2954–62.
[35] Qian F, et al. Immunogenicity of self-associated aggregates and chemically
cross-linked conjugates of the 42 kDa Plasmodium falciparum merozoite surface
protein-1. PLoS ONE 2012;7(6):pe36996.
[36] Miyata T, et al. Plasmodium vivax ookinete surface protein Pvs25 linked
to cholera toxin B subunit induces potent transmission-blocking immunity by intranasal as well as subcutaneous immunization. Infect Immun
2010;78(9):3773–82.
[37] Miyata T, et al. Tricomponent immunopotentiating system as a novel
molecular design strategy for malaria vaccine development. Infect Immun
2011;79(10):4260–75.
[38] Kubler-Kielb J, et al. Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25.
Proc Natl Acad Sci USA 2007;104(1):293–8.
[39] Kubler-Kielb J, et al. A bicomponent Plasmodium falciparum investigational
vaccine composed of protein–peptide conjugates. Proc Natl Acad Sci USA
2010;107(3):1172–7.
[40] Watson DS, Endsley AN, Huang L. Design considerations for liposomal vaccines:
inﬂuence of formulation parameters on antibody and cell-mediated immune
responses to liposome associated antigens. Vaccine 2012;30(13):2256–72.
[41] Wurz GT, et al. Tecemotide: an antigen-speciﬁc cancer immunotherapy. Hum
Vaccin Immunother 2014;10(11):3383–93.
[42] van Dissel JT, et al. A novel liposomal adjuvant system, CAF01, promotes longlived Mycobacterium tuberculosis-speciﬁc T-cell responses in human. Vaccine
2014;32(52):7098–107.
[43] Cummings JF, et al. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with
AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2
CD4+ T cells but does not protect against experimental Plasmodium falciparum
infection. Vaccine 2010;28(31):5135–44.
[44] Spring MD, et al. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.
PLoS ONE 2009;4(4):pe5254.
[45] Otsyula N, et al. Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium
falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01. Malar J 2013;12:p29.
[46] Fox CB, et al. A nanoliposome delivery system to synergistically trigger TLR4
AND TLR7. J Nanobiotechnol 2014;12:p17.
[47] Noe AR, et al. A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas ﬂuorescens platform as a malaria
vaccine candidate. PLoS ONE 2014;9(9):pe107764.
[48] Agger EM, et al. Cationic liposomes formulated with synthetic mycobacterial
cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS ONE 2008;3(9):pe3116.
[49] Pinto VV, et al. The effect of adjuvants on the immune response induced by
a DBL4varepsilon-ID4 VAR2CSA based Plasmodium falciparum vaccine against
placental malaria. Vaccine 2012;30(3):572–9.
[50] Moon JJ, et al. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction.
Proc Natl Acad Sci USA 2012;109(4):1080–5.
[51] Fox CB, Haensler J. An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants. Expert Rev Vaccines 2013;12(7):747–58.
[52] Mata E, et al. Malaria vaccine adjuvants: latest update and challenges in preclinical and clinical research. Biomed Res Int 2013;2013:p282913.

[53] Wu Y, et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS ONE
2008;3(7):pe2636.
[54] McCarthy JS, et al. A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine
containing 2 isoforms of MSP2 formulated with Montanide(R) ISA 720. PLoS
ONE 2011;6(9):pe24413.
[55] Kester KE, et al. Randomized, double-blind, phase 2a trial of falciparum malaria
vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efﬁcacy,
and immunologic associates of protection. J Infect Dis 2009;200(3):337–46.
[56] Fox CB, et al. TLR4 ligand formulation causes distinct effects on antigen-speciﬁc
cell-mediated and humoral immune responses. Vaccine 2013;31(49):5848–55.
[57] Fox CB, et al. Effects on immunogenicity by formulations of emulsion-based
adjuvants for malaria vaccines. Clin Vaccine Immunol 2012;19(10):1633–40.
[58] Lumsden JM, et al. Evaluation of immune responses to a Plasmodium vivax
CSP-based recombinant protein vaccine candidate in combination with secondgeneration adjuvants in mice. Vaccine 2012;30(22):3311–9.
[59] Wikman M, et al. General strategies for efﬁcient adjuvant incorporation of
recombinant subunit immunogens. Vaccine 2005;23(17–18):2331–5.
[60] Przysiecki C, et al. Sporozoite neutralizing antibodies elicited in mice and rhesus
macaques immunized with a Plasmodium falciparum repeat peptide conjugated
to meningococcal outer membrane protein complex. Front Cell Infect Microbiol
2012;2:p146.
[61] Leleux J, Roy K. Micro and nanoparticle-based delivery systems for vaccine
immunotherapy: an immunological and materials perspective. Adv Healthc
Mater 2013;2(1):72–94.
[62] Moon JJ, et al. Antigen-displaying lipid-enveloped PLGA nanoparticles
as delivery agents for a Plasmodium vivax malaria vaccine. PLoS ONE
2012;7(2):pe31472.
[63] Dinglasan RR, et al. Single-dose microparticle delivery of a malaria
transmission-blocking vaccine elicits a long-lasting functional antibody
response. Curr Mol Med 2013;13(4):479–87.
[64] Chroboczek J, Szurgot I, Szolajska E. Virus-like particles as vaccine. Acta Biochim
Pol 2014;61(3):531–9.
[65] Fox CB, et al. Working together: interactions between vaccine antigens and
adjuvants. Ther Adv Vaccines 2013;1(1):7–20.
[66] Aucouturier J, Ascarateil S, Dupuis L. The use of oil adjuvants in therapeutic
vaccines. Vaccine 2006;24(Suppl 2) (p. S2-44-5).
[67] Morelli AB, et al. ISCOMATRIX: a novel adjuvant for use in prophylactic and
therapeutic vaccines against infectious diseases. J Med Microbiol 2012;61(Pt
7):935–43.
[68] Hem SL, Hogenesch H. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev
Vaccines 2007;6(5):685–98.
[69] Kaslow D, et al. RTS, S: Towards a ﬁrst lanmark on the malaria vaccine technology roadmap. Vaccine 2015;33(52):7425–32.
101
102
103
104
105
106
107

ClinicalTrials.gov Identiﬁer: NCT02013687
ClinicalTrials.gov Identiﬁers: NCT01434381 and NCT01867463
ClinicalTrials.gov Identiﬁer: NCT02334462
ClinicalTrials.gov identiﬁer NCT02044198
ClinicalTrials.gov identiﬁer: NCT02174978
ClinicalTrials.gov identiﬁer: NCT01157897
ClinicalTrials.gov Identiﬁers: NCT01540474, NCT02014727,
and NCT01949909

200
201
202
203
204

Kaslow et al., [69]
Narum, Jennings, Wu, manuscript in preparation
Talaat et al., manuscript in preparation
Narum et al., manuscript in preparation
Jones et al., manuscript accepted by PLOS ONE: A Method for
Producing Protein Nanoparticles with Applications in Vaccines.

